CRIS
Price
$1.63
Change
-$0.03 (-1.81%)
Updated
Aug 1 closing price
Capitalization
19.44M
DERM
Price
$7.00
Change
-$0.36 (-4.90%)
Updated
Aug 1, 04:59 PM (EDT)
Capitalization
73.35M
10 days until earnings call
NTLA
Price
$11.49
Change
-$0.15 (-1.29%)
Updated
Aug 1, 04:59 PM (EDT)
Capitalization
1.19B
96 days until earnings call
Interact to see
Advertisement

CRIS or DERM or NTLA

Header iconCRIS vs DERM vs NTLA Comparison
Open Charts CRIS vs DERM vs NTLABanner chart's image
Curis
Price$1.63
Change-$0.03 (-1.81%)
Volume$60.48K
Capitalization19.44M
Journey Medical
Price$7.00
Change-$0.36 (-4.90%)
Volume$1.13K
Capitalization73.35M
Intellia Therapeutics
Price$11.49
Change-$0.15 (-1.29%)
Volume$103.29K
Capitalization1.19B
CRIS vs DERM vs NTLA Comparison Chart in %
Loading...
CRIS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DERM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (CRIS: $1.66DERM: $7.34NTLA: $11.64)
Brand notoriety: CRIS and NTLA are not notable and DERM is notable
CRIS and NTLA are part of the Biotechnology industry, and DERM is in the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: CRIS: 33%, DERM: 58%, NTLA: 126%
Market capitalization -- CRIS: $19.44M, DERM: $73.35M, NTLA: $1.19B
$CRIS [@Biotechnology] is valued at $19.44M. $NTLA’s [@Biotechnology] market capitalization is $ $1.19B. $DERM [@Pharmaceuticals: Other] has a market capitalization of $ $73.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $ $213.98B to $ $0. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $ $77.48B to $ $0. The average market capitalization across the [@Biotechnology] industry is $ $2.34B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $ $3.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRIS’s FA Score shows that 0 FA rating(s) are green whileDERM’s FA Score has 0 green FA rating(s), and NTLA’s FA Score reflects 1 green FA rating(s).

  • CRIS’s FA Score: 0 green, 5 red.
  • DERM’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, DERM and NTLA are a better buy in the long-term than CRIS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRIS’s TA Score shows that 3 TA indicator(s) are bullish while DERM’s TA Score has 5 bullish TA indicator(s), and NTLA’s TA Score reflects 3 bullish TA indicator(s).

  • CRIS’s TA Score: 3 bullish, 6 bearish.
  • DERM’s TA Score: 5 bullish, 2 bearish.
  • NTLA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, DERM is a better buy in the short-term than NTLA, which in turn is a better option than CRIS.

Price Growth

CRIS (@Biotechnology) experienced а -9.78% price change this week, while DERM (@Pharmaceuticals: Other) price change was -4.30% , and NTLA (@Biotechnology) price fluctuated -8.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.32%. For the same industry, the average monthly price growth was +16.82%, and the average quarterly price growth was +37.20%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.53%. For the same industry, the average monthly price growth was +4.44%, and the average quarterly price growth was +79.95%.

Reported Earning Dates

CRIS is expected to report earnings on May 06, 2025.

DERM is expected to report earnings on Nov 05, 2025.

NTLA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Other (-2.53% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.19B) has a higher market cap than DERM($73.4M) and CRIS($19.4M). DERM YTD gains are higher at: 87.724 vs. NTLA (-0.172) and CRIS (-45.752). DERM has higher annual earnings (EBITDA): -5.69M vs. CRIS (-40.26M) and NTLA (-530.8M). NTLA has more cash in the bank: 504M vs. DERM (24.7M) and CRIS (20.3M). DERM has less debt than CRIS and NTLA: DERM (131K) vs CRIS (2.64M) and NTLA (119M). DERM has higher revenues than NTLA and CRIS: DERM (79.9M) vs NTLA (45.6M) and CRIS (11.2M).
CRISDERMNTLA
Capitalization19.4M73.4M1.19B
EBITDA-40.26M-5.69M-530.8M
Gain YTD-45.75287.724-0.172
P/E RatioN/AN/AN/A
Revenue11.2M79.9M45.6M
Total Cash20.3M24.7M504M
Total Debt2.64M131K119M
FUNDAMENTALS RATINGS
CRIS vs DERM vs NTLA: Fundamental Ratings
CRIS
DERM
NTLA
OUTLOOK RATING
1..100
512176
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
68
Overvalued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100100
SMR RATING
1..100
1009696
PRICE GROWTH RATING
1..100
954041
P/E GROWTH RATING
1..100
10042100
SEASONALITY SCORE
1..100
n/a38n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (30) in the Biotechnology industry is in the same range as CRIS (60) and is somewhat better than the same rating for DERM (68). This means that NTLA's stock grew similarly to CRIS’s and somewhat faster than DERM’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRIS (100) and is in the same range as DERM (100). This means that NTLA's stock grew similarly to CRIS’s and similarly to DERM’s over the last 12 months.

NTLA's SMR Rating (96) in the Biotechnology industry is in the same range as DERM (96) and is in the same range as CRIS (100). This means that NTLA's stock grew similarly to DERM’s and similarly to CRIS’s over the last 12 months.

DERM's Price Growth Rating (40) in the Biotechnology industry is in the same range as NTLA (41) and is somewhat better than the same rating for CRIS (95). This means that DERM's stock grew similarly to NTLA’s and somewhat faster than CRIS’s over the last 12 months.

DERM's P/E Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for NTLA (100) and is somewhat better than the same rating for CRIS (100). This means that DERM's stock grew somewhat faster than NTLA’s and somewhat faster than CRIS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRISDERMNTLA
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
N/A
Bullish Trend 9 days ago
87%
Bullish Trend 10 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CRIS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DERM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AEGOF7.26N/A
N/A
Aegon Ltd.
LPKFF10.36N/A
N/A
Lpkf Laser & Electronics AG
PLDGP54.75N/A
N/A
Prologis, Inc.
CLPMF0.16N/A
N/A
Clip Money Inc.
TPZEF18.66-0.35
-1.83%
TOPAZ ENERGY CORP.